» Articles » PMID: 34236569

Programmed Cell Death, Redox Imbalance, and Cancer Therapeutics

Overview
Journal Apoptosis
Publisher Springer
Date 2021 Jul 8
PMID 34236569
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells are disordered by nature and thus featured by higher internal redox level than healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain threshold, rendering therapeutic strategies relying on redox control a possible cancer management solution. Yet, various programmed cell death events have been consecutively discovered, complicating our understandings on their associations with redox imbalance and clinical implications especially therapeutic design. Thus, it is imperative to understand differences and similarities among programmed cell death events regarding their associations with redox imbalance for improved control over these events in malignant cells as well as appropriate design on therapeutic approaches relying on redox control. This review addresses these issues and concludes by bringing affront cold atmospheric plasma as an emerging redox controller with translational potential in clinics.

Citing Articles

A gene signature related to programmed cell death to predict immunotherapy response and prognosis in colon adenocarcinoma.

Zheng L, Lu J, Kong D, Zhan Y PeerJ. 2025; 13:e18895.

PMID: 39950044 PMC: 11823652. DOI: 10.7717/peerj.18895.


Copper in the colorectal cancer microenvironment: pioneering a new era of cuproptosis-based therapy.

Feng Q, Sun Y, Yang Z, Wang Z, Chen Z, Liu F Front Oncol. 2025; 14():1522919.

PMID: 39850821 PMC: 11754209. DOI: 10.3389/fonc.2024.1522919.


Unveiling Varied Cell Death Patterns in Lung Adenocarcinoma Prognosis and Immunotherapy Based on Single-Cell Analysis and Machine Learning.

Song Z, Zhang W, Zhu M, Wang Y, Zhou D, Cao X J Cell Mol Med. 2024; 28(22):e70218.

PMID: 39602465 PMC: 11601877. DOI: 10.1111/jcmm.70218.


Cold Atmospheric Plasma: Possible Cure of Autoimmune Disorders and Cancer via Attenuating Inflammation.

Dai X, Feng S, Zheng Y Int J Biol Sci. 2024; 20(14):5436-5449.

PMID: 39494336 PMC: 11528447. DOI: 10.7150/ijbs.102445.


Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.

He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X Signal Transduct Target Ther. 2024; 9(1):209.

PMID: 39138145 PMC: 11322379. DOI: 10.1038/s41392-024-01891-4.


References
1.
Acharya A, Das I, Chandhok D, Saha T . Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010; 3(1):23-34. PMC: 2835886. DOI: 10.4161/oxim.3.1.10095. View

2.
Raza M, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S . ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol. 2017; 143(9):1789-1809. DOI: 10.1007/s00432-017-2464-9. View

3.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

4.
Hock J, Krishnan V, Onyia J, Bidwell J, Milas J, Stanislaus D . Osteoblast apoptosis and bone turnover. J Bone Miner Res. 2001; 16(6):975-84. DOI: 10.1359/jbmr.2001.16.6.975. View

5.
KERR J, Wyllie A, Currie A . Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26(4):239-57. PMC: 2008650. DOI: 10.1038/bjc.1972.33. View